General
Pharmaceutical company Pfizer asks US regulators to allow emergency use of its experimental COVID-19 vaccine
Pharmaceutical company Pfizer has formally asked US regulators to allow emergency use of its COVID-19 vaccine, starting the clock on a process that could bring limited first shots as early as next month.
Key points:
- How much vaccine is available and when is a moving target, but initial supplies will be scarce
- Globally, Pfizer has estimated it could have 50 million doses available by year’s end
- The US Government has a contract to buy millions of Pfizer-BioNTech doses
The action comes days after Pfizer Inc and its German partner BioNTech announced that its vaccine appeared 95 per cent effective at preventing mild to severe COVID-19 disease in a large, ongoing study.
The companies said protection plus a good safety record meant the vaccine…
-
Business24 hours agoASX 200 plunges as US tariffs fall-out continues
-
General13 hours ago‘We are here for you’: PM to bring help to flood zones
-
Noosa News24 hours agoPolice to get on-the-spot protection powers for DV victims
-
General12 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening